Stemline Therapeutics, part of the Menarini Group, is focused on the development and commercialization of novel oncology therapeutics. ELZONRIS® (tagraxofusp-erzs) is a CD-123 targeted therapy approved for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients 2 years and older. Clinical trials in CMML, MF and AML are ongoing. Our pipeline includes: felezonexor (XPO1 inhibitor; Phase 1), SL-701 (immunotherapeutic; Phase 2 in GBM complete), SL-901 (kinase inhibitor; Phase 1), and SL-1001 (RET inhibitor, pre-IND).
Brands: https://stemline.com/wp-content/uploads/2021/04/ASCO_Banner.jpg
Show Specials
Press Releases